Cloud DX Inc (CVE:CDX) announced that it has been issued a US patent for its upcoming Pulsewave 2.0 vital sign monitor, a wearable home care device capable of simultaneously capturing diagnostic-quality blood pressure, heart rate, heartbeat irregularities and respiration rate.
US Patent 11,006,843 titled “System And Method Of Determining Breathing Rates From Oscillometric Data,” protects Cloud DX's method for determining the breathing rate of a patient using an oscillometric device as the physiological sensor and positions Pulsewave 2.0 as the first home-based vital signs monitor of its kind able to capture such a wide swath of diagnostic data.
The Pulsewave 2.0 is worn on the wrist and oscillometric waveforms are obtained from pulses in the patent’s arteries as they breathe and the cuff deflates. Pulsewave software analyzes these signals and produces breathing rate data. When the device is connected to the internet, physicians can derive additional biological metrics from the data via the Cloud Diagnostics online platform, the company said.
READ: Cloud DX teams up with Maple and Curatio to build comprehensive coronavirus remote home care platform
Pulsewave 2.0 is currently in clinical trials at Dalhousie Medicine New Brunswick. The Pulsewave program is supported by the NextGen Manufacturing Supercluster and the New Brunswick Health Research Foundation. Pulsewave and the Cloud Diagnostics platform are protected by multiple US and international patents.
"Home-based diagnostics are the next frontier of virtual care,” CEO Robert Kaul said in a statement. “Healthcare providers and patients are now seeing first-hand the limitations of telehealth and are pressing for a more all-encompassing model of care where telemedicine, home-based patient vitals monitoring and in-person doctor visits work seamlessly together to inform medical diagnosis and treatment.
“The ability to capture patient vitals — including an accurate respiration rate — in an ongoing, comprehensive way and to have that data flow directly from the patient's body to the care team, will greatly speed accurate clinical decision making, contribute to better patient outcomes, and make care more efficient and more economic for providers and payers.”
Pulsewave 2.0 builds and expands on a near decade of experience deploying the original Pulsewave 1.0, which the company says was the world's first cloud-based portable blood pressure device. Pulsewave 1.0 has gathered millions of pulse wave signals from tens of thousands of individuals, and its accuracy and precision were validated in a real-world setting in an independent peer-reviewed study published by the University of New Brunswick and the New Brunswick Heart Centre, where researchers determined that the Cloud DX device was similar in accuracy to an intra-arterial catheter for blood pressure.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel